Connor, Clark & Lunn Investment Management (CC&L)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,263
| Closed | -$44.7K | – | 1499 |
|
|
2022
Q4 | $44.7K | Sell |
1,263
-359
| -22% | -$12.7K | ﹤0.01% | 1153 |
|
|
2022
Q3 | $366K | Buy |
1,622
+1,143
| +239% | +$258K | ﹤0.01% | 877 |
|
|
2022
Q2 | $91K | Sell |
479
-293
| -38% | -$55.7K | ﹤0.01% | 985 |
|
|
2022
Q1 | $192K | Buy |
+772
| New | +$192K | ﹤0.01% | 948 |
|
|
2020
Q4 | – | Sell |
-417
| Closed | -$102K | – | 1071 |
|
|
2020
Q3 | $102K | Sell |
417
-2,176
| -84% | -$532K | ﹤0.01% | 873 |
|
|
2020
Q2 | $747K | Sell |
2,593
-189
| -7% | -$54.4K | 0.01% | 675 |
|
|
2020
Q1 | $567K | Buy |
2,782
+2,303
| +481% | +$469K | 0.01% | 664 |
|
|
2019
Q4 | $214K | Buy |
+479
| New | +$214K | ﹤0.01% | 826 |
|
|
2016
Q1 | – | Sell |
-46
| Closed | -$30K | – | 913 |
|
|
2015
Q4 | $30K | Hold |
46
| – | – | ﹤0.01% | 799 |
|
|
2015
Q3 | $22K | Buy |
+46
| New | +$22K | ﹤0.01% | 702 |
|
|
2015
Q2 | – | Sell |
-79
| Closed | -$676K | – | 675 |
|
|
2015
Q1 | $676K | Buy |
79
+55
| +229% | +$471K | 0.01% | 359 |
|
|
2014
Q4 | $213K | Buy |
+24
| New | +$213K | ﹤0.01% | 518 |
|